CPU0213, a novel endothelin type A and type B receptor antagonist, protects against myocardial ischemia/reperfusion injury in rats

Brazilian Journal of Medical and Biological Research

Volumn 44, Issue 11, 2011, Pages 1148-1155

  Wang, Z Y ^a   Zhang, W ^b   Li, X Z ^b   Han, Y ^c   Chen, Y P ^a   Liu, Z ^b   Xie, L P ^b   Ji, Y ^b   Lu, X ^a  

^a Second Affiliated Hospital   (China)

^b Atherosclerosis Research Centre   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Akt; Endothelin receptor antagonist; eNOS; Myocardial ischemia reperfusion injury

Indexed keywords

1 BUTYL 3 [2,4 BIS(4 CHLOROBENZYLOXY)PHENYL]PYRAZOLE 5 CARBOXYLIC ACID; CPU 0213; CREATINE KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; LACTATE DEHYDROGENASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IN VIVO STUDY; INFLAMMATION; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALIA; RATTUS;

EID: 80555146633     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2011007500119     Document Type: Article

References (40)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
2. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 2001; 41: 851-876.
3. + channels in ETB-induced relaxation. Br J Pharmacol 2005; 146: 903-912.
4. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morrell NW, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002; 165: 398-405.
5. Han B, Ghanim D, Peleg A, Uretzky G, Hasin Y. Loss of systemic endothelial function post-PCI. Acute Card Care 2008; 10: 79-87.
6. Vago H, Soos P, Zima E, Geller L, Keltai K, Roka A, et al. Changes of endothelin-1 and big endothelin-1 levels and action potential duration during myocardial ischemiareperfusion in dogs with and without ventricular fibrillation. J Cardiovasc Pharmacol 2004; 44 (Suppl 1): S376-S379.
7. Goyal SN, Bharti S, Arora S, Golechha M, Arya DS. Endothelin receptor antagonist BQ-123 ameliorates myocardial ischemic-reperfusion injury in rats: a hemodynamic, biochemical, histopathological and electron microscopic evidence. Biomed Pharmacother 2010; 64: 639-646.
8. Eitel I, Nowak M, Stehl C, Adams V, Fuernau G, Hildebrand L, et al. Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging. Am Heart J 2010; 159: 882-890.
9. Climent B, Fernandez N, Garcia-Villalon AL, Monge L, Sanchez A, Dieguez G. Effects of antagonists for endothelin ET(A) and ET(B) receptors on coronary endothelial and myocardial function after ischemia-reperfusion in anesthetized goats. Vascul Pharmacol 2006; 44: 384-390.
10. Ozdemir R, Parlakpinar H, Polat A, Colak C, Ermis N, Acet A. Selective endothelin a (ETA) receptor antagonist (BQ-123) reduces both myocardial infarct size and oxidant injury. Toxicology 2006; 219: 142-149.
11. Singh AD, Amit S, Kumar OS, Rajan M, Mukesh N. Cardioprotective effects of bosentan, a mixed endothelin type A and B receptor antagonist, during myocardial ischaemia and reperfusion in rats. Basic Clin Pharmacol Toxicol 2006; 98: 604-610.
12. Richard V, Kaeffer N, Hogie M, Tron C, Blanc T, Thuillez C. Role of endogenous endothelin in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats: studies with bosentan, a mixed ETA-ETB antagonist. Br J Pharmacol 1994; 113: 869-876.
13. Bohm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res 2007; 76: 8-18.
14. Qi MY, Xia HJ, Dai DZ, Dai Y. A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to up-regulation of the expression of FKBP12.6, SERCA2a, and PLB in rats. J Cardiovasc Pharmacol 2006; 47: 729-735.
15. Feng Y, Dai DZ, Na T, Cui B, Wang T, Zhang Y, et al. Endothelin receptor antagonist CPU0213 suppresses ventricular fibrillation in L-thyroxin induced cardiomyopathy. Pharmacol Rep 2007; 59: 306-314.
16. Yip HK, Wu CJ, Chang HW, Yang CH, Yu TH, Chen YH, et al. Prognostic value of circulating levels of endothelin-1 in patients after acute myocardial infarction undergoing primary coronary angioplasty. Chest 2005; 127: 1491-1497.
17. Jesmin S, Zaedi S, Shimojo N, Iemitsu M, Masuzawa K, Yamaguchi N, et al. Endothelin antagonism normalizes VEGF signaling and cardiac function in STZ-induced diabetic rat hearts. Am J Physiol Endocrinol Metab 2007; 292: E1030-E1040.
18. Konrad D, Oldner A, Wanecek M, Rudehill A, Weitzberg E, Biber B, et al. Positive inotropic and negative lusitropic effects of endothelin receptor agonism in vivo. Am J Physiol Heart Circ Physiol 2005; 289: H1702-H1709.
19. Eszlari E, Czobel M, Molnar G, Bogats G, Kaszaki J, Nagy S, et al. Modulation of cardiac contractility through endothelin-1 release and myocardial mast cell degranulation. Acta Physiol Hung 2008; 95: 267-285.
20. Qi XL, Sia YT, Stewart DJ, Wei G, Nguyen QT, Cernacek P, et al. Myocardial contractile responsiveness to endothelin-1 in the post-infarction rat model of heart failure: effects of chronic quinapril. J Mol Cell Cardiol 2001; 33: 2023-2035.
21. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 1982; 66: 1146-1149.
22. Jennings RB, Reimer KA. Factors involved in salvaging ischemic myocardium: effect of reperfusion of arterial blood. Circulation 1983; 68: I-25-I-36.
23. Lavallee M, Cox D, Patrick TA, Vatner SF. Salvage of myocardial function by coronary artery reperfusion 1, 2, and 3 hours after occlusion in conscious dogs. Circ Res 1983; 53: 235-247.
24. Brunner F, Leonhard B, Kukovetz WR, Mayer B. Role of endothelin, nitric oxide and L-arginine release in ischaemia/ reperfusion injury of rat heart. Cardiovasc Res 1997; 36: 60-66.
25. Rossi P, Wanecek M, Konrad D, Oldner A. Tezosentan counteracts endotoxin-induced pulmonary edema and improves gas exchange. Shock 2004; 21: 543-548.
26. He HB, Dai DZ, Dai Y. CPU0213, a novel endothelin receptor antagonist, ameliorates septic renal lesion by suppressing ET system and NF-kappaB in rats. Acta Pharmacol Sin 2006; 27: 1213-1221.
27. Yanagisawa M, Inoue A, Ishikawa T, Kasuya Y, Kimura S, Kumagaye S, et al. Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci U S A 1988; 85: 6964-6967.
28. Sawamura T, Kimura S, Shinmi O, Sugita Y, Kobayashi M, Mitsui Y, et al. Characterization of endothelin converting enzyme activities in soluble fraction of bovine cultured endothelial cells. Biochem Biophys Res Commun 1990; 169: 1138-1144.
29. Verma S, Maitland A, Weisel RD, Li SH, Fedak PW, Pomroy NC, et al. Hyperglycemia exaggerates ischemia-reperfusion- induced cardiomyocyte injury: reversal with endothelin antagonism. J Thorac Cardiovasc Surg 2002; 123: 1120-1124.
30. Maulik N, Yoshida T, Das DK. Oxidative stress developed during the reperfusion of ischemic myocardium induces apoptosis. Free Radic Biol Med 1998; 24: 869-875.
31. Loomis ED, Sullivan JC, Osmond DA, Pollock DM, Pollock JS. Endothelin mediates superoxide production and vasoconstriction through activation of NADPH oxidase and uncoupled nitric-oxide synthase in the rat aorta. J Pharmacol Exp Ther 2005; 315: 1058-1064.
32. Cheng TH, Shih NL, Chen SY, Wang DL, Chen JJ. Reactive oxygen species modulate endothelin-I-induced c-fos gene expression in cardiomyocytes. Cardiovasc Res 1999; 41: 654-662.
33. Dong F, Zhang X, Wold LE, Ren Q, Zhang Z, Ren J. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol 2005; 145: 323-333.
34. Gao F, Yao CL, Gao E, Mo QZ, Yan WL, McLaughlin R, et al. Enhancement of glutathione cardioprotection by ascorbic acid in myocardial reperfusion injury. J Pharmacol Exp Ther 2002; 301: 543-550.
35. von Dobschuetz E, Hoffmann T, Messmer K. Inhibition of neutrophil proteinases by recombinant serpin Lex032 reduces capillary no-reflow in ischemia/reperfusion-induced acute pancreatitis. J Pharmacol Exp Ther 1999; 290: 782-788.
36. Niccoli G, Lanza GA, Shaw S, Romagnoli E, Gioia D, Burzotta F, et al. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. Eur Heart J 2006; 27: 1793-1798.
37. Gonon AT, Gourine AV, Middelveld RJ, Alving K, Pernow J. Limitation of infarct size and attenuation of myeloperoxidase activity by an endothelin A receptor antagonist following ischaemia and reperfusion. Basic Res Cardiol 2001; 96: 454-462.
38. Liu S, Premont RT, Kontos CD, Huang J, Rockey DC. Endothelin-1 activates endothelial cell nitric-oxide synthase via heterotrimeric G-protein betagamma subunit signaling to protein jinase B/Akt. J Biol Chem 2003; 278: 49929-49935.
39. Hoshino S, Kikuchi Y, Nakajima M, Kimura H, Tsuyama S, Uemura K, et al. Endothelial NO synthase (eNOS) phosphorylation regulates coronary diameter during ischemiareperfusion in association with oxidative stress. Free Radic Res 2005; 39: 481-489.
40. Shemyakin A, Bohm F, Wagner H, Efendic S, Bavenholm P, Pernow J. Enhanced endothelium-dependent vasodilatation by dual endothelin receptor blockade in individuals with insulin resistance. J Cardiovasc Pharmacol 2006; 47: 385-390.